Novartis to buy Imperial-Crick spinout Myricx Bio for up to $1.5 billion
The London biotech went from a 2019 GBP 4.5 million seed round to a pharma exit after shifting NMT inhibitors into ADC payloads.
By Ryan Merket · Published

The London biotech went from a 2019 GBP 4.5 million seed round to a pharma exit after shifting NMT inhibitors into ADC payloads.